Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $127.7252W HIGH $200.44
Volume
718.42 K
Value Traded
112.99 M
Short % Float
6.12%
+2.42%Week
-1.74%1 Month
-19.04%3 Month
-21.93%6 Month
-72.46%5 Year
+1,009.22%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
10.34 B
EPS (TTM)
5.82
P/E Ratio
24.81
Ent. Value
9.24 B
Total Shares
71.60 M
Float Shares
68.68 M
Insiders
3.32%
Institutions
105.26%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
ALGN Catalyst Timeline
Dated clinical, regulatory and corporate events for Align Technology, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Align Technology, Inc.
1Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage
Event history 1
Past FDA Catalysts and PDUFA Decisions
How ALGN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Align Technology, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every ALGN program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Vitalone Britt J.Director | Option | -1,443 1,443 held | $0.00 | 05/20/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ALGN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| PARKMAN HEALTHCARE PARTNERS LLC | 0.6 % (50 %) | 6.23 M | 36.96 K | 74.08% ( 15.73 K) |
ALGN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ALGN ranks across every disease it competes in
Competitive Position is a premium feature
See how ALGN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialALGN News
ALGNAlign Technology to Announce Third Quarter 2026 Results on October 28, 2026
Align Technology, a leader in medical devices, will announce its third quarter 2026 financial results on October 28, 2026. The results will be made public after the market closes at 4:00 p.m. ET. This announcement indicates the company's commitment to transparency and investor communication.
Read more →ALGNAlign Technology Launches “SHIFT Happens” U.S. Campaign to Educate Adults About Lifelong Tooth Movement
Align Technology has launched the 'SHIFT Happens' campaign aimed at educating adults about lifelong tooth movement. This initiative is designed to assist Invisalign-trained doctors in connecting with consumers. The campaign emphasizes the importance of understanding tooth movement over time, promoting better dental health awareness.
Read more →ALGNAlign Technology to Speak at Upcoming Financial Conference
Align Technology, Inc. announced its participation in an upcoming financial conference. The company, known for its Invisalign System and digital orthodontics solutions, will present at the event. Investors can access the presentation through a live webcast on Align's Investor Relations website.
Read more →ALGNQuentin Blackford to Join Align Technology Board of Directors
Align Technology has appointed Quentin Blackford, the President and CEO of iRhythm Technologies, to its Board of Directors. This strategic move aims to bolster the company's leadership and enhance its capabilities in the medical device sector. Blackford's extensive experience is expected to contribute positively to Align's growth and innovation.
Read more →ALGNAlign Technology Prevails in China Patent Infringement Action Against Angelalign
Align Technology has achieved a legal victory in a patent infringement case against Angelalign in China. The Jinan Intermediate People's Court ruled in favor of Align, affirming its intellectual property rights. This decision is expected to bolster Align's competitive stance in the Chinese market.
Read more →ALGNAlign Technology Hosts 2026 Invisalign® Ortho Summit, Showcasing a “Beyond Possible” Vision for Connected Digital Orthodontics
Align Technology hosted the 2026 Invisalign Ortho Summit in Las Vegas, gathering over 500 orthodontists and practice team members. The event highlighted advancements in digital orthodontics under the theme 'Beyond Possible.' This reflects Align's commitment to innovation in the field.
Read more →ALGNAlign Technology Announces Strategic Initiatives Consistent with Long-term Growth and Shareholder Value Creation Objectives
Align Technology has announced strategic initiatives aimed at enhancing long-term growth and shareholder value. The company is committed to strong corporate governance and has engaged in discussions with Elliott Investment Management to align its objectives. These initiatives reflect Align's focus on innovation in digital orthodontics and restorative dentistry.
Read more →ALGNAlign Technology Announces Second Quarter 2026 Financial Results
Align Technology reported its Q2 2026 financial results, showing total revenues of $1,056.2 million. This represents a 1.5% increase sequentially and a 4.3% increase year-over-year. Despite the positive revenue growth, the company noted that total revenues were adversely affected by unspecified factors.
Read more →ALGNAlign Technology Announces New Innovations to Advance Invisalign® Treatment Planning and Enhance Patient Engagement Through Its Integrated Align™ Digital Platform
Align Technology has announced new innovations to its integrated Align Digital Platform, aimed at enhancing the Invisalign treatment planning process. These advancements are designed to improve visualization and treatment predictability for healthcare providers. The updates also focus on increasing patient engagement, showcasing Align's commitment to advancing digital orthodontics.
Read more →ALGNOperation Smile Announces Align Technology as Title Sponsor of 34th International Student Leadership Conference for Sixth Year
Align Technology has been announced as the title sponsor for Operation Smile's 2026 International Student Leadership Conference, marking its sixth consecutive year of support. The partnership has contributed nearly $3.8 million to student programs, facilitating access to surgical care for students from low- and middle-income countries. The conference will take place in Bangkok, Thailand, with around 280 participants from 37 countries, highlighting the global impact of youth-led health advocacy.
Read more →ALGN▲ +7.6%on this news
Align Technology to Announce Second Quarter 2026 Results on July 29, 2026
Align Technology is set to announce its financial results for the second quarter of 2026 on July 29, 2026. This announcement is part of the company's regular reporting schedule. Further details regarding the results will be provided during the announcement.
Read more →ALGN▲ +7.6%on this newsshared move
Align Technology Statement on European Commission Proceeding
Align Technology has issued a statement regarding a proceeding by the European Commission. The details of the proceeding are not specified in the article. The company aims to address any concerns raised by the regulatory body. Further information may be released as the situation develops.
Read more →ALGNAlign Technology Announces Board Leadership Transition. C. Raymond Larkin, Jr. to Retire as Chairman and Kevin Conroy to be Appointed Chairman Effective July 1, 2026
Align Technology has announced a leadership transition within its board. C. Raymond Larkin, Jr. will retire as Chairman, and Kevin Conroy is set to take over the role effective July 1, 2026. This change marks a significant shift in the company's governance structure.
Read more →ALGNAlign Technology Awards Funding to Universities Worldwide for Advancing Orthodontic and Dental Research
Align Technology has announced funding for universities around the globe to support advancements in orthodontic and dental research. This initiative aims to foster innovation and collaboration in the field, potentially leading to improved treatment options. The funding reflects Align's commitment to enhancing dental care through research.
Read more →ALGNAlign Technology Expands Global Operations With Plans for New Multi-Million Dollar Manufacturing Facility in Hyderabad, India
Align Technology has announced plans to establish a new manufacturing facility in Hyderabad, India, representing a significant investment in its global operations. This expansion aims to enhance production capabilities and meet increasing demand. The new facility is expected to create numerous job opportunities in the region.
Read more →ALGNAlign Technology Hosts 400 Doctors at 2026 Invisalign® EMEA Ortho Summit Featuring Digital Orthodontic Solutions Focused on Clinical Indications and Upcoming Align Innovations
Align Technology hosted 400 doctors at the 2026 Invisalign EMEA Ortho Summit. The event focused on digital orthodontic solutions and highlighted clinical indications as well as upcoming innovations from Align. This gathering aimed to enhance knowledge and collaboration among orthodontic professionals.
Read more →ALGN▲ +5.3%on this newsshared move
Align Technology to Speak at Upcoming Financial Conferences
Align Technology is scheduled to speak at upcoming financial conferences. Details regarding the specific conferences and topics to be discussed have not been provided in the article. This announcement highlights the company's ongoing engagement with investors and the financial community.
Read more →ALGNAlign Technology Announces $200 Million Open Market Repurchase
Align Technology has announced a plan to repurchase $200 million of its common stock through open market transactions. This initiative is part of a larger $1.0 billion stock repurchase program that has been approved by the company. The move is expected to bolster shareholder value and reflects Align's strong financial position.
Read more →ALGNAlign Technology Showcases Latest Advances in Integrated Digital Orthodontics and Previews 2026 Innovation at AAO Annual Session
Align Technology previewed its latest innovations in digital orthodontics at the AAO 2026 Annual Session. Key highlights include the Invisalign Specifix 3D Printed Attachment System, integrated buttons, and a new palatal expander. These advancements aim to enhance treatment predictability and efficiency for orthodontists. The company emphasizes its commitment to improving patient outcomes through integrated digital solutions.
Read more →ALGNAlign Technology Announces First Quarter 2026 Financial Results, $200M Stock Repurchase, and Reaffirms Fiscal 2026 Guidance
Align Technology reported its Q1 2026 financial results, showing a 6.2% increase in total revenues year-over-year, amounting to $1,040.1 million. The company also announced a $200 million stock repurchase program and reaffirmed its fiscal 2026 guidance. However, there was a slight sequential decline of 0.7% in revenues.
Read more →About Align Technology, Inc.
Headquarters410 NORTH SCOTTSDALE ROAD, SUITE 1300, TEMPE, AZ, 85288
Founded1997
BIOPHARMAWATCH ELITE PLUS
Trade the next ALGN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime